Thanks CPR. That pretty much addresses most of my questions. So there is no IP on methoxyflurane. There is IP on the delivery device, and there is arguably some moat around the manufacture of the drug.
Not rock solid, but good enough to hopefully become the 800 pound gorilla in the market before others get interested in trying to create a generic product.
Is that how everyone is interpreting it? I'd be interested in how others are assessing this risk.
Questions from new investors, page-8
Add MVP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.0¢ |
Change
-0.015(3.30%) |
Mkt cap ! $38.83M | |||
| Open | High | Low | Value | Volume |
| 45.0¢ | 45.0¢ | 44.0¢ | $7.448K | 16.59K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 25448 | 44.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.5¢ | 18084 | 3 |
View Market Depth
| Last trade - 11.01am 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
45.0¢ |
Change
-0.015 ( 1.10 %) |
||||
| Open | High | Low | Volume | ||
| 45.0¢ | 45.0¢ | 44.0¢ | 8143 | ||
| Last updated 11.36am 07/05/2024 ? | |||||
| MVP (ASX) Chart |